Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. However, during the past two decades, there have been major changes in government and private support of womens health research -- in policies, regulations, and the organization of research efforts. In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that womens health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change.

This report, Womens Health Diagnostic Testing Markets provides insight into this key area of testing. The following tests are among those covered in this report.

• Pregnancy and Ovulation Tests

• Bone Density Testing

• Prenatal Screening

• Ultrasound

• Mammography

• Pap Smears

• Colposcopy

• HPV Testing

• Ovarian Cancer Tests

• UTI Testing

• Neonatal Jaundice Testing

• Auto Immune Disease Testing

• Cystic Fibrosis Testing

Women make more than 75% of the health care decisions in American households and spend almost two of every three health care dollars. Women also make more than 65% of physician visits, 62% of prescription drug purchases, and 76% of the nursing home population. The life expectancy of women is longer than for men and is climbing steadily due to advancements in medicine. Yet, female health is an area that has much room for improvement both in the development of products and the treatment of diseases.

This report analyzes the current and potential world markets for key diagnostic tests targeted at womens health. This report generally forecasts future market growth for these tests to 2015. Market segments covered include the world and North American markets. This report also reviews the nature and direction of research and trends, and gives insight into some issues facing the industry.

The report profiles several key companies, including large companies that have made names for themselves in the field, as well as smaller firms with market niches. These companies are involved in developing and marketing over the counter (OTC), point of care (POC) in vitro diagnostic (IVD) tests and screening systems. Some of the companies profiled include

• GE Healthcare

• Hologic

• Perkin Elmer

• Philips Healthcare

• Siemens Healthcare

• Somagen Diagnostics.

Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data are generated into multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives and researchers.

CHAPTER ONE: EXECUTIVE SUMMARY

1.1 Womens Health in Focus

1.2 Diagnostics Moving Forward

1.2.1 Advancing Female Health

1.2.2 Studying the Most Relevant Groups

1.2.3 Translating Research into Practice

1.3 Key Issues Involving Womens Health

1.4 Market Picture

1.4.1 Overall Trends

1.4.2 Key Diagnostic Forecasts

1.4.3 Methodology

 

CHAPTER TWO: INTRODUCTION

2.1 Perspective on Womens Health

2.2 Key Differences between the Sexes

2.2.1 Autoimmune Disease

2.2.2 Cancer

2.2.3 Musculoskeletal Health

2.2.4 Birth Defects

2.2.5 Urinary Tract Infections

2.3 Key Leading Causes of Death in Females

2.4 Demographics

2.4.1 What Claims Womens Lives

2.5 Key Trends and Issues in Womens Diagnostics

2.5.1 Understanding the Molecular Basis of Disease

2.5.2 Managing Cancer Disease and Costs

2.5.3 Ultrasound and Mammography Use Grows

 

CHAPTER THREE: PREGNANCY AND OVULATION

3.1 Perspective on Testing

3.1.1 Digital Testing

3.2 OTC Test Market Forecast

3.3 Church & Dwight Co. Inc.

3.4 Inverness Medical Innovations

3.5 Siemens Healthcare Diagnostics

CHAPTER FOUR: BONE DENSITY TESTING

4.1 Alarming Rise of Osteoporosis

4.1.1 Bone Mineral Density

4.1.2 Refining Diagnosis

4.2 Bone Densitometer Market Forecast

4.3 GE Healthcare

4.4 Hologic

4.5 Osteometer MediTech

CHAPTER FIVE: PRENATAL SCREENING

5.1 Perspective

5.1.1 Advances

5.2 Value of Informed Choice

5.3 The Impact of Prenatal Genetic Testing

5.4 DNA Assay Market Forecast

5.5 PerkinElmer

5.6 Quest Diagnostics

5.7 Sequenom

CHAPTER SIX: ULTRASOUND

6.1 History and Perspective

6.1.1 Advances in Technology

6.2 Obstetrics and Gynecology

6.3 Breast Imaging

6.4 Market Forecasts

6.4.1 Ob/Gyn Market

6.4.2 Breast Imaging

6.5 Analogic

6.6 Philips Healthcare

6.7 Siemens Healthcare

CHAPTER SEVEN: MAMMOGRAPHY

7.1 Perspective

7.1.1 Routine Screening

7.2 Transitioning to Digital

7.3 Computer-Aided Detection

7.4 Market Forecasts

7.4.1 Mammography Systems

7.4.2 CAD

7.5 Carestream Health

7.6 FujiFilm Medical Systems USA

7.7 GE Healthcare

7.8 Hologic

CHAPTER EIGHT: PAP SMEARS

8.1 Testing for Cervical Cancer

8.1.1 Types of Screening

8.2 Cervical Cancer Shot

8.3 A Market Need

8.3.1 IVD Market Forecasts

8.4 Becton Dickinson

8.5 Hologic

8.6 Innogenetics NV

CHAPTER NINE: COLPOSCOPY

9.1 Biopsy Procedure

9.1.1 Pap Smear Concerns

9.1.2 Routine Use

9.2 Markets for Colposcopy Systems

9.2.1 Primary and Secondary Screening

9.3 CooperSurgical 95 Corporate Dr. Trumbull, CT 06611

9.4 Guided Therapeutics

9.5 NeoDiagnostix

CHAPTER TEN: HPV TESTING

10.1 HPV Defined

10.1.1 High Risk Types

10.1.2 Relationship to Cervical Cancer

10.2 Vaccine Issues

10.3 Strong Market Expected

10.3.1 IVD Market Forecasts

10.4 Abbott Diagnostics

10.5 Hologic

10.6 Qiagen Benelux BV

CHAPTER ELEVEN: OVARIAN CANCER

11.1 Types of Ovarian Cancer

11.2 Different Diagnostic Techniques

11.3 Tumor Markers and Antigens

11.4 CA-125 Market Forecast

11.5 Abbott Diagnostics

11.6 Fujirebio Diagnostics

CHAPTER TWELVE: URINARY TRACT INFECTIONS

12.1 Leading Cause of Morbidity and Death

12.1.1 Impact of Hospital Acquired Infections

12.1.2 Impact on Women

12.2 E. coli the Key Culprit

12.3 Market Forecasts Molecular Testing

12.4 Amerifit

12.5 Liofilchem

12.6 Rheonix

12.7 Somagen Diagnostics

CHAPTER THIRTEEN: NEONATAL JAUNDICE

13.1 Issues Involving Bilirubin

13.2 Two Factors in Neonates

13.3 Risk Factors

13.4 Autism Link

13.5 Market Forecasts Bilirubin Testing

13.6 Instrumentation Laboratory

13.7 Nova Biomedical

13.8 Siemens Healthcare Diagnostics

13.9 Wako Diagnostics

CHAPTER FOURTEEN: AUTOIMMUNE DISEASE

14.1 Genetic Factors

14.2 Low-Level Autoimmunity

14.3 Impact on Females

14.4 Types of Autoimmune Disease

14.5 IVD Market Forecasts

14.6 Bio-Rad Laboratories

14.7 Kronus

14.8 Phadia

14.9 XDx

CHAPTER FIFTEEN: CYSTIC FIBROSIS

15.1 Affecting the Entire Body

15.2 Reduced Life Expectancy

15.3 Genetics

15.4 Chronic Infections

15.5 Market Forecast Genetic Testing

15.6 AutoGenomics

15.7 GenMark Diagnostics

15.8 Gen-Probe

15.9 Luminex

15.10 Sequenom